Consumption of the epidermis: A criterion in the differential diagnosis of melanoma and dysplastic nevi that is associated with increasing Breslow depth and ulceration

American Journal of Dermatopathology

Volumn 29, Issue 6, 2007, Pages 527-533

  Walters, Ruth Fulghum ^a   Groben, Pamela A ^a   Busam, Klaus ^b   Millikan, Robert C ^a   Rabinovitz, Harold ^c   Cognetta, Armand ^d   Mihm Jr , Martin C ^e   Prieto, Victor G ^f   Googe, Paul B ^g,h   King, Roy ^g   Moore, Dominic T ^a   Woosley, John ^a   Thomas, Nancy E ^a,i  

^a UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d Dermatology Associates of Tallahassee   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE   (United States)

^h VANDERBILT UNIVERSITY   (United States)

ⁱ UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Dermatology; Dysplastic nevus; Mitosis; Pathology; Ulceration

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CARCINOMA IN SITU; CHILD; CONTROLLED STUDY; DISEASE COURSE; DYSPLASTIC NEVUS; FEMALE; HISTOPATHOLOGY; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MELANOMA; NEWBORN; PRIORITY JOURNAL; SKIN BIOPSY; SKIN ULCER; STATISTICAL SIGNIFICANCE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR BIOPSY; TUMOR GROWTH;

ADULT; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; DYSPLASTIC NEVUS SYNDROME; EPIDERMIS; FEMALE; FLORIDA; HUMANS; MALE; MELANOMA; MIDDLE AGED; NORTH CAROLINA; PRECANCEROUS CONDITIONS; PROGNOSIS; SKIN NEOPLASMS; SKIN ULCER;

EID: 36348988457     PISSN: 01931091     EISSN: None     Source Type: Journal    
DOI: 10.1097/DAD.0b013e318156e0a7     Document Type: Article

References (36)

1. American Cancer Society. Cancer Facts and Figures 2007. Atlanta, Ga: American Cancer Society; 2007.
2. Farmer ER, Gonin R, Hanna MP. Discordance in the histopathologic diagnosis of melanoma and melanocytic nevi between expert pathologists. Hum Pathol. 1996;27:528-531.
3. Brochez L, Verhaeghe E, Grosshans E, et al. Inter-observer variation in the histopathological diagnosis of clinically suspicious pigmented skin lesions. J Pathol. 2002;196:459-466.
4. Massi G, LeBoit PE. Histological Diagnosis of Nevi and Melanoma. Darmstadt, Germany: Steinkopff Verlag Darmstadt; 2004.
5. Okun MR, Edelstein LM, Kasznica J, et al. What criteria reliably distinguish melanoma from benign melanocytic lesions? Histopathology. 2000;37:464-472.
6. Hantschke M, Bastian BC, LeBoit PE. Consumption of the epidermis: a diagnostic criterion for the differential diagnosis of melanoma and Spitz nevus. Am J Surg Pathol. 2004;28:1621-1625.
7. Barnhill RL, Piepkorn M, Busam K. Pathology of Melanocytic Nevi and Malignant Melanoma. 2nd ed. New York, NY: Springer-Verlag; 2004.
8. Barnhill RL. Current status of the dysplastic melanocytic nevus. J Cutan Pathol. 1991;18:147-159.
9. Urso C, Rongioletti F, Innocenzi D, et al. Histological features used in the diagnosis of melanoma are frequently found in benign melanocytic naevi. J Clin Pathol. 2005;58:409-412.
10. Braun-Falco M, Friedrichson E, Ring J. Subepidermal cleft formation as a diagnostic marker for cutaneous malignant melanoma. Hum Pathol. 2005;36:412-415.
11. Ackerman A, Jacobson M, Vitale P. Clue 34. In: Ackerman A, Jacobson M, Vitale P, eds. Clues to the Diagnosis in Dermatopathology. Chicago, Ill: ASCP Press; 1991:133-136.
12. Millikan RC, Hummer A, Begg C, et al. Polymorphisms in nucleotide excision repair genes and risk of multiple primary melanoma: the Genes Environment and Melanoma Study. Carcinogenesis. 2006;27:610-618.
13. Begg CB, Hummer AJ, Mujumdar U, et al. A design for cancer case-control studies using only incident cases: experience with the GEM study of melanoma. Int J Epidemiol. 2006;35:756-764.
14. Elbaum M, Kopf AW, Rabinovitz HS, et al. Automatic differentiation of melanoma from melanocytic nevi with multispectral digital dermoscopy: a feasibility study. J Am Acad Dermatol. 2001;44:207-218.
15. Clark WH Jr, Mihm MC Jr. Lentigo maligna and lentigo-maligna melanoma. Am J Pathol. 1969;55:39-67.
16. McGovern VJ, Mihm MC Jr, Bailly C, et al. The classification of malignant melanoma and its histologic reporting. Cancer. 1973;32:1446-1457.
17. Elder DE, Green MH, Guerry DT, et al. The dysplastic nevus syndrome: our definition. Am J Dermatopathol. 1982;4:455-460.
18. Mihm MC Jr, Googe PB, Tong AKF, et al. Problematic Pigmented Lesions: A Case Method Approach. Philadelphia, Pa: Lea & Febiger; 1990.
19. Clark WH Jr, From L, Bernardino EA, et al. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res. 1969;29:705-727.
20. Elder DE, Murphy GF. Malignant tumors (melanoma and related lesions). In: Rosai J, Sobin L, eds. Melanocytic Tumors of the Skin. Washington, DC: Armed Forces Institute of Pathology; 1991:130.
21. Shea CR, Vollmer RT, Prieto VG. Correlating architectural disorder and cytologic atypia in Clark (dysplastic) melanocytic nevi. Hum Pathol. 1999;30:500-505.
22. Crowson N, Magro CN, Mihm MC Jr. Dysplastic melanocytic nevi, de novo intraepidermal epithelioid and lentiginous melanocytic dysplasias, and nevi at specific anatomic sites. In: The Melanocytic Proliferations: A Comprehensive Textbook of Pigmented Lesions. New York, NY: Wiley-Liss; 2001:225-280.
23. Green A, Swerdlow AJ. Epidemiology of melanocytic nevi. Epidemiol Rev. 1989;11:204-221.
24. Gallagher RP, McLean DI. The epidemiology of acquired melanocytic nevi. A brief review. Dermatol Clin. 1995;13:595-603.
25. MacLennan R, Kelly JW, Rivers JK, et al. The Eastern Australian Childhood Nevus Study: site differences in density and size of melanocytic nevi in relation to latitude and phenotype. J Am Acad Dermatol. 2003;48:367-375.
26. Autier P, Boniol M, Severi G, et al. Sex differences in numbers of nevi on body sites of young European children: implications for the etiology of cutaneous melanoma. Cancer Epidemiol Biomarkers Prev. 2004;13:2003-2005.
27. Slater DN. Doubt and uncertainty in the diagnosis of melanoma. Histopathology. 2000;37:469-472.
28. Braun-Falco M. Cleft formation and consumption of the epidermis in cutaneous melanocytic lesions - reply. Hum Pathol. 2006;37:247.
29. Vogt T, Brunnberg S, Hohenleutner U, et al. Bullous malignant melanoma: an unusual differential diagnosis of a hemorrhagic friction blister. Dermatol Surg. 2003;29:102-104.
30. Akasu R, From L, Kahn HJ. Characterization of the mononuclear infiltrate involved in regression of halo nevi. J Cutan Pathol. 1994;21:302-311.
31. Musette P, Bachelez H, Flageul B, et al. Immune-mediated destruction of melanocytes in halo nevi is associated with the local expansion of a limited number of T cell clones. J Immunol. 1999;162:1789-1794.
32. LeBoit PE. Homonymous epidermotropism. Am J Dermatopathol. 2004;26:81-83.
33. Hsu MY, Meier F, Herlyn M. Melanoma development and progression: a conspiracy between tumor and host. Differentiation. 2002;70:522-536.
34. Hofmann UB, Houben R, Brocker EB, et al. Role of matrix metalloproteinases in melanoma cell invasion. Biochimie. 2005;87:307-314.
35. Huntington JT, Shields JM, Der CJ, et al. Overexpression of collagenase 1 (MMP-1) is mediated by the ERK pathway in invasive melanoma cells: role of BRAF mutation and fibroblast growth factor signaling. J Biol Chem. 2004;279:33168-33176.
36. Scolyer RA, Shaw HM, Thompson JF, et al. Interobserver reproducibility of histopathologic prognostic variables in primary cutaneous melanomas. Am J Surg Pathol. 2003;27:1571-1576.